Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens (Webcourse)

Format: Webcourse

Credit(s): 1.00 (60 min)

Release Date: Jul 29, 2022

Expiration Date: Jul 29, 2023

Credit Type(s):

Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

Metastatic pancreatic cancer is a serious malignancy with limited treatment options and poor outcomes. It is also growing in incidence, and it is projected to be the second leading cause of cancer-related death before 2030. Treatment of pancreatic cancer relies primarily on chemotherapy, though targeted therapies are now available for the approximately 20% of patients who express actionable genetic alterations. Additionally, novel targeted therapies and immunotherapies are showing promise in early phase clinical trials, providing potential future treatment options for this deadly malignancy.

Selection between currently available treatment options and ongoing clinical trials relies heavily on biomarkers, as well as performance status, comorbidities, and patient preference. Communicating with patients regarding the importance of biomarker testing, treatment selection, and clinical trials is key to ensuring the best outcomes for patients with metastatic pancreatic cancer.

This activity, Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens, will provide oncology clinicians with information on the most recent biomarkers and treatments for metastatic pancreatic cancer, expert recommendations for treatment selection and sequencing, and updated information on emerging biomarkers and targeted therapies for pancreatic cancer.